Clinical Trial

LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma

Recruiting
View on ClinicalTrials.gov →
Summary
A prospective, single-arm, open-label dose-exploration and expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor efficacy characteristics of LCAR-F33S in patients with relapsed/refractory multiple myeloma(Investigator-initiated Study).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-07-30.
Status change: Not Yet Recruiting → Recruiting 2025-12-25
Trial Details
NCT Number NCT07100067
Lead Sponsor Nanjing Legend Biotech Co.
Collaborators: Institute of Hematology & Blood Diseases Hospital, China
Conditions Relapsed/Refractory Multiple Myeloma(MM)
Enrollment 35 participants
Start Date 2025-09-16
Primary Completion 2028-02-20 (estimated)
Study Completion 2029-11-20 (estimated)
Updated on ClinicalTrials.gov 2025-12-29